Cue Biopharma, Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2019. Financial amounts below are in U.S. dollars; millions are used unless noted. Cue is a clinical-stage biopharmaceutical company developing its Immuno-STAT platform and had no commercial product revenue.
Financial results and liquidity
| Metric | Q3 2019 | Q3 2018 | Nine months 2019 | Nine months 2018 |
|---|---|---|---|---|
| Collaboration revenue | $0.984m | $0.449m | $2.409m | $0.812m |
| Operating expenses | $8.078m | $13.208m | $30.163m | $28.542m |
| Net loss | $6.990m | $12.559m | $27.782m | $27.359m |
| Basic and diluted loss per share | $0.31 | $0.62 | $1.30 | $1.36 |
- Cash and liquidity: Cash and cash equivalents were $31.379m at September 30, 2019, with an additional $0.150m of long-term restricted cash. Current assets were $32.990m and current liabilities $10.392m, implying working capital of approximately $22.598m. No marketable securities remained at quarter-end.
- Cash flow: Operating activities used $24.359m in the first nine months, versus $22.513m a year earlier. Investing activities provided $18.592m, primarily from investment maturities; financing activities provided $16.296m, primarily from the ATM stock offering. Cash, cash equivalents and restricted cash increased $10.529m to $31.529m.
- Debt and obligations: The balance sheet reports no borrowings. Operating lease liabilities totaled $7.044m, including $4.434m current; the filing lists $7.044m in future lease obligations. Other liabilities include $8.410m of research and development contract liabilities.
- Gross margin is not meaningful because revenue came from collaboration arrangements, not product sales. Operating loss was $7.094m in Q3 2019 and $27.754m for the nine-month period.
Changes versus prior comparable periods
- Q3 collaboration revenue more than doubled year over year, while nine-month revenue nearly tripled, primarily reflecting work under the Merck and LG Chem collaborations.
- Q3 operating expenses fell $5.130m year over year, mainly from lower R&D headcount, stock compensation, laboratory spending and drug-substance manufacturing costs. Nine-month operating expenses rose $1.621m: lower R&D expense was more than offset by higher G&A expense.
- Q3 net loss narrowed by $5.569m; the nine-month net loss increased $0.423m. Nine-month operating cash use increased $1.846m.
- Cash and cash equivalents increased from $20.800m at December 31, 2018, supported by the ATM offering and redemption of short-term investments. Shares outstanding increased from 20.697m to 22.970m during that period.
Business developments, outlook and risks
- The FDA accepted the IND for lead candidate CUE-101 in May 2019, and the company initiated clinical trials during Q3. CUE-102, targeting WT1, was described as a preclinical program.
- LG Chem paid a $2.5m milestone following FDA acceptance of the CUE-101 IND. Cue recognized $0.810m of LG Chem-related collaboration revenue in Q3 and $1.535m for the first nine months; the corresponding Merck amounts were $0.174m and $0.874m. The company reported no milestone or royalty revenue to date apart from the disclosed LG Chem IND milestone, and no variable consideration beyond that milestone was included in the transaction price at quarter-end.
- Management said cash on hand and funds available through its ATM program were expected to fund operations for the next 12 months from issuance of the financial statements. The $30m ATM program had generated approximately $15.7m net proceeds by September 30; continued operations and expanded R&D depend on securing additional capital. Further equity financing could dilute existing shareholders.
- Management expects R&D and G&A spending to increase as clinical development and operations expand. Key risks include clinical and regulatory setbacks, safety or inconclusive trial results, reliance on collaborators and licensors, and the need for additional financing. The company reported no material change in previously disclosed risk factors.
- ASC 842 adoption resulted in recognition of lease right-of-use assets and liabilities, without a material net impact on reported operations or accumulated deficit. The company reported no material legal proceedings or off-balance-sheet arrangements. Disclosure controls were assessed as effective at September 30, 2019.
Important facts for investors to verify
- Clinical progress, enrollment, safety and results for CUE-101, and the timing and costs of subsequent development.
- Cash burn and runway against management’s 12-month estimate, including the amount and terms of any additional financing.
- ATM capacity remaining and the potential dilution from future share issuance, options and warrants.
- Collaboration revenue recognition, remaining contract liabilities, milestone conditions and partners’ termination or option rights.
- Future lease payments and research, licensing and clinical-development commitments as programs advance.